IDNA vs. IBRN

Last updated Jun 24, 2026

IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and IBRN (iShares Neuroscience and Healthcare ETF) are both Health & Biotech Equities funds from iShares - IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index while IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index. Both are passively managed. Over the past 3 years, IDNA returned 11.16%/yr vs 14.72%/yr for IBRN. A 0.79 correlation means they provide meaningful diversification when combined. Both charge a 0.47% expense ratio.

Performance

IDNA vs. IBRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and iShares Neuroscience and Healthcare ETF (IBRN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, IDNA achieves a 19.52% return, which is significantly higher than IBRN's 14.14% return.

IDNA

• 1D: 1.53%
• 1M: 6.29%
• YTD: 19.52%
• 6M: 16.84%
• 1Y: 54.42%
• 3Y*: 11.16%
• 5Y*: -8.18%
• 10Y*: —

IBRN

• 1D: 0.60%
• 1M: 6.49%
• YTD: 14.14%
• 6M: 14.25%
• 1Y: 71.08%
• 3Y*: 14.72%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IDNA vs. IBRN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	19.52%	17.26%	-0.72%	-7.63%	-20.65%
IBRN iShares Neuroscience and Healthcare ETF	14.14%	28.49%	-2.78%	0.92%	2.87%

Correlation

The correlation between IDNA and IBRN is 0.80, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.80
Correlation (3Y) Calculated over the trailing 3-year period	0.78
Correlation (All Time) Calculated using the full available price history since Aug 26, 2022	0.79

The correlation between IDNA and IBRN has been stable across timeframes, ranging from 0.78 to 0.80 - a consistent structural relationship.

IDNA vs. IBRN - Sectors Allocation Comparison

Sectors	IDNA	IBRN
Healthcare	99.3%	100.0%
Industrials	0.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IDNA vs. IBRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA

IDNA Risk / Return Rank: 74
IDNA Sharpe Ratio Rank: 72
IDNA Sortino Ratio Rank: 71
IDNA Omega Ratio Rank: 60
IDNA Calmar Ratio Rank: 89
IDNA Martin Ratio Rank: 78

IBRN

IBRN Risk / Return Rank: 89
IBRN Sharpe Ratio Rank: 90
IBRN Sortino Ratio Rank: 88
IBRN Omega Ratio Rank: 80
IBRN Calmar Ratio Rank: 96
IBRN Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. IBRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and iShares Neuroscience and Healthcare ETF (IBRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	IDNA	IBRN	Difference
Sharpe ratio: Return per unit of total volatility	2.19	2.80	-0.61
Sortino ratio: Return per unit of downside risk	3.03	3.71	-0.68
Omega ratio: Gain probability vs. loss probability	1.34	1.43	-0.09
Calmar ratio: Return relative to maximum drawdown	5.13	8.12	-2.99
Martin ratio: Return relative to average drawdown	14.30	22.92	-8.62

IDNA vs. IBRN - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 2.19, which is comparable to the IBRN Sharpe Ratio of 2.80. The chart below compares the historical Sharpe Ratios of IDNA and IBRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

IDNA vs. IBRN - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than IBRN's maximum drawdown of -35.38%. Use the drawdown chart below to compare losses from any high point for IDNA and IBRN.

Drawdown Indicators

	IDNA	IBRN	Difference
Max Drawdown Largest peak-to-trough decline	-68.26%	-35.38%	-32.88%
Max Drawdown (1Y) Largest decline over 1 year	-10.66%	-8.80%	-1.86%
Max Drawdown (3Y) Largest decline over 3 years	-29.46%	-35.38%	+5.92%
Max Drawdown (5Y) Largest decline over 5 years	-68.26%	—	—
Current Drawdown Current decline from peak	-41.07%	0.00%	-41.07%
Average Drawdown Average peak-to-trough decline	-36.28%	-9.75%	-26.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.82%	3.11%	+0.71%

Volatility

IDNA vs. IBRN - Volatility Comparison

The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 7.33%, while iShares Neuroscience and Healthcare ETF (IBRN) has a volatility of 8.17%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than IBRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IDNA	IBRN	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.33%	8.17%	-0.84%
Volatility (6M) Calculated over the trailing 6-month period	18.45%	19.20%	-0.75%
Volatility (1Y) Calculated over the trailing 1-year period	24.96%	25.50%	-0.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.47%	25.36%	+3.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	29.51%	25.36%	+4.15%

IDNA vs. IBRN - Expense Ratio Comparison

Both IDNA and IBRN have an expense ratio of 0.47%.

Dividends

IDNA vs. IBRN - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 0.90%, more than IBRN's 0.87% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
IBRN iShares Neuroscience and Healthcare ETF	0.87%	0.99%	0.40%	0.06%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	0.90%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Frequently Asked Questions

Can I hold both IDNA and IBRN in my portfolio?

IDNA and IBRN have a correlation of 0.80, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, IDNA or IBRN?

IBRN has higher volatility (8.17%) compared to IDNA (7.33%). In terms of maximum drawdown, IDNA dropped -68.26% vs IBRN's -35.38%.

Which ETF is better, IDNA or IBRN?

On 3-year performance, IBRN leads with 14.72% vs 11.16% for IDNA. Both ETFs have the same 0.47% expense ratio. On volatility, IDNA has been the lower-risk option at 7.33%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, IDNA or IBRN?

Over the 3-year period, IBRN has performed better with a 14.72% return vs 11.16%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, IDNA or IBRN?

IDNA and IBRN have the same expense ratio: 0.47% per year.

Which ETF pays a higher dividend yield, IDNA or IBRN?

IDNA has the higher dividend yield at 0.90%, compared with 0.87% for IBRN.

What is the main difference between IDNA and IBRN?

IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while IBRN tracks NYSE FactSet Global Neuro Biopharma and MedTech Index.

Which has better risk-adjusted returns?

IBRN currently has the higher Sharpe Ratio (2.80 vs 2.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.